UK Authorizes Once-Weekly Insulin for Type 2 Diabetes

Original Article: https://www.medscape.com/viewarticle/mhra-authorises-once-weekly-insulin-type-2-diabetes-2026a10012py

The Announcement

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Onswik (insulin efsitora alfa), a long-acting basal insulin administered once a week for adults with type 2 diabetes. Announced on October 13, 2026, the treatment offers an alternative to daily basal insulin injections and could reduce the number of injections from as many as 365 per year to 52.

What Researchers Found

Clinical trials found that once-weekly insulin efsitora alfa provided blood sugar control comparable to daily basal insulins. The treatment is designed to maintain insulin activity over a longer period, potentially making insulin therapy easier to manage for some adults with type 2 diabetes.

Why This Matters

Daily insulin injections can be challenging for people who have difficulty administering medication or remembering frequent doses. A weekly option may reduce this burden and could be particularly helpful for some people who rely on caregivers for their injections. However, the treatment still requires careful medical supervision, and low blood sugar (hypoglycemia) is its most commonly reported adverse reaction.

The Takeaway

The UK authorization of once-weekly insulin introduces a new option for adults with type 2 diabetes who need basal insulin. By reducing injection frequency while providing blood sugar control comparable to daily basal insulin, Onswik may make treatment more convenient for some patients. Its suitability will depend on individual needs, safety considerations, and clinical guidance.